logo
Man who let snakes bite him 200 times spurs new antivenom hope

Man who let snakes bite him 200 times spurs new antivenom hope

eNCA3 days ago

PARIS - Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him.
Four days later, he woke up from a coma.
"I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin.
This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time.
From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times.
Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home.
After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists.
But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom.
The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom.
AFP/File | Tony KARUMBA
This would fill a major need, because currently, most antivenoms only cover one or a few of the world's 600 venomous snakes.
Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization.
These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas.
- 'Pain every time' -
Friede's first bite was from a harmless garter snake when he was five years old.
"I was afraid, I cried, I ran away," said Friede, now 57.
Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted.
Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom.
How antivenom is made has changed little over the last 125 years.
Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom.
However, this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from a horse that can cause serious side-effects, including anaphylactic shock.
"I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said.
He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes.
"There is pain every time," he said.
- 'Proud' -
For years, the scientists he contacted to take advantage of his immunity refused to bite.
Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom.
Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites.
When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood."
AFP/File | Tony KARUMBA
"I've been waiting for this call for a long time," came the response, Glanville said.
The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib.
It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six.
The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia.
Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies.
Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down.
Friede said he was "proud" to have made a "small difference" in medical history.
Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues.
But he hopes to get bitten by snakes again in the future.
"I do miss it," he said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Men's mental health awareness month: Addressing the silent crisis in South Africa
Men's mental health awareness month: Addressing the silent crisis in South Africa

IOL News

time5 hours ago

  • IOL News

Men's mental health awareness month: Addressing the silent crisis in South Africa

As South Africa and the global community mark Men's Mental Health Awareness Month, the spotlight turns to a disturbing reality: men are overwhelmingly represented in the country's suicide statistics, yet the conversation around their mental health is quiet. According to alarming statistics, South Africa ranks 10th on the list of countries with the most suicides, with international figures reporting in 2022 that 13,774 suicides were reported, 10,861 of them men. This means that men account for nearly 80% of all recorded suicides in the country. This staggering figure raises questions about the societal, psychological, and systemic factors driving so many men to the edge. While the topic of mental health and mental health awareness is something often talked about, the conversation around men's mental health is muted. In many communities, expectations require men to be stoic and strong providers, while discouraging any type of emotional expression and help-seeking. Risk factors for suicide may include unemployment and occupational issues, divorce and adverse childhood experiences. To make matters worse, mental health services in South Africa are underfunded and often inaccessible, especially for those in lower-income communities. Statistics from the World Health Organization reveal that Africa has the highest suicide rate worldwide. It added that this is driven by a combination of factors, including poverty, unemployment, and untreated mental health issues.

South Africa is actively monitoring a new Covid-19 variant known as Nimbus, says Health Minister
South Africa is actively monitoring a new Covid-19 variant known as Nimbus, says Health Minister

Daily Maverick

time20 hours ago

  • Daily Maverick

South Africa is actively monitoring a new Covid-19 variant known as Nimbus, says Health Minister

South Africa is actively monitoring the emergence of a new Covid-19 variant known as Nimbus or NB.1.8.1, Health Minister Aaron Motsoaledi told the G20 Health Working on Tuesday morning. Motsoaledi also praised the recent adoption of the World Health Organization Pandemic Agreement, and called on global partners to work together towards its implementation. New Covid variant South Africa is actively monitoring the emergence of a new Covid-19 variant known as Nimbus or NB.1.8.1, Health Mimister Aaron Motsoaledi told the G20 Health Working Group, which he addressed on Tuesday The variant is a descendant of the Omicron lineage, meaning that current recommendations for SARS-CoV-2 vaccines are still effective and no new public health actions are required. 'I wish to reassure this esteemed gathering that South Africa has robust surveillance systems in place. Our National Institute for Communicable Diseases manages a comprehensive sentinel surveillance programme that systematically tests for key respiratory viruses, including SARS-CoV-2, influenza and RSV [respiratory syncytial virus],' he said. 'Currently, our data shows very low SARS-CoV-2 activity. While we are observing a seasonal increase in influenza, we are well prepared to manage this.' Motsoaledi said the Health Department would continue to monitor the situation and would report any significant changes. Motsoaledi called for the assembled member states to support 'critical' steps in reaching implementation of the recently adopted World Health Organization (WHO) Pandemic Agreement. 'As an active participant and representative member for the African region, I can say with certainty that we see this agreement as a crucial step towards rectifying the deep-seated imbalances in access to life-saving pandemic products that were so painfully exposed during the recent [Covid-19] crisis,' said Motsoaledi. 'We now call upon the elevated political will of all G20 members and our global partners to overcome the entrenched commercial interests and diplomatic hurdles that stand in our way.' The 78th World Health Assembly in Geneva, Switzerland, formally adopted the Pandemic Agreement in May – a move Motsoaledi described as a 'landmark achievement for global health governance'. However, he noted that the work required to transform the agreement from a document of principles to a 'life-saving tool for justice and our shared global health security' was far from over. Tuesday's meeting was the fourth time the Health Working Group has convened since South Africa's G20 presidency activities kicked off. The group's mandate is to improve global health by addressing challenges, building resilient systems and promoting equitable access to services. WHO Pandemic Agreement The adoption of the Pandemic Agreement came after more than three years of intensive negotiations launched by governments in response to the impacts of the Covid-19 pandemic. Precious Matsoso, the former director-general of the South African Department of Health, co-chaired the Intergovernmental Negotiating Body that coordinated the process to draft and negotiate the agreement. The agreement sets out principles, approaches and tools for better international coordination towards pandemic prevention and responsiveness across a range of areas, including through the 'equitable and timely access to vaccines, therapeutics and diagnostics', according to the WHO. Motsoaledi explained that the agreement was built on several key pillars aimed at fundamentally reshaping the approach to global health emergencies. These included: A firm commitment to equitable, timely and affordable access to pandemic-related health products, particularly for countries in need; The establishment of a global supply chain and logistics network to enhance the distribution of critical resources; The creation of a dedicated coordinating financial mechanism to support countries in building their pandemic prevention, preparedness and response capacities; and A 'holistic 'One Health' approach' which recognises the interconnectedness of human, animal and environmental health. 'The centrepiece of this agreement, and the key to unlocking its full potential for equity, is the Pathogen Access and Benefit-Sharing (PABS) system. This innovative mechanism will require pharmaceutical manufacturers to contribute 20% of their production during pandemic emergencies in return for access to pathogen data,' said Motsoaledi. 'We are now entering a critical new phase. The detailed negotiations on the PABS system annexure will commence immediately through an intergovernmental working group. The first meeting to elect the bureau for this group must take place before 15 July, and it is rightly anticipated that the leadership will reflect a balance between the Global North and the Global South.' Motsoaledi called the negotiations to finalise the PABS system a political test that would demonstrate member states' collective will to move 'beyond rhetoric' towards delivering tangible results. 'Let us seize this moment. Let us work together with renewed urgency and unwavering resolve to complete the remaining vital task,' he said. The Pandemic Agreement has been adopted at a time when global health financing has been thrown into crisis by the decision of the US administration under President Donald Trump to withdraw foreign aid spending from a range of health programmes, including the President's Emergency Plan for Aids Relief (Pepfar). The US also announced its withdrawal from the WHO in January. The US has been absent from many G20-related engagements, though President Cyril Ramaphosa announced in May that Trump had agreed that the US would participate in the forthcoming G20 summit, according to a Business Day report. Daily Maverick has asked the Department of Health whether the US was represented at the fourth meeting of the Health Working Group, and its response will be added when it becomes available.

Red tape stops SA kids from getting ADHD meds
Red tape stops SA kids from getting ADHD meds

TimesLIVE

timea day ago

  • TimesLIVE

Red tape stops SA kids from getting ADHD meds

Attention deficit and hyperactivity disorder (ADHD) affects between 5% and 7% of schoolgoing children, but because doctors can only prescribe treatment for a month at a time, many kids in South Africa, especially those who can't afford monthly doctor's visits, don't access medication regularly. Methylphenidate, a central nervous system stimulant that can significantly reduce symptoms in about 70% of users with the condition and that the World Health Organization (WHO) recommends for the treatment of ADHD, helps people with ADHD to concentrate better, and to be less impulsive and overactive. Studies have shown that when the methylphenidate — the gold standard for ADHD treatment — is used correctly, children's school marks improve and they become better equipped to develop social skills. In other words, effective ADHD treatment doesn't just help schoolgoers with ADHD to sit still and focus in class, but it also supports them to learn and socialise — outcomes that form the foundation of a healthy and productive adulthood. Methylphenidate is, however, classified as a schedule six drug in South Africa, placing it in the same regulatory category as medicines with a high potential for abuse. Pharmacies are therefore only allowed to dispense the medicine to people with doctors' prescriptions, and by law, physicians can only prescribe 30 days' worth of methylphenidate treatment at a time. This means patients need to visit their doctor each month for a new prescription, so in the private sector they'd need to pay for a doctor's visit each month, on top of paying for the medication, and in the public sector patients would need to take a day each month to queue up at their local clinic — and they'd have to make sure it's a day on which a doctor, as opposed to only nurses, are available at their health facility. The current scheduling, as a result, creates huge administrative and financial difficulties for patients and caregivers when they try to get treated, especially for those navigating ADHD's very symptoms: executive dysfunction, forgetfulness and inattention. As a psychiatrist, working in both the public and private healthcare sector, I've seen first hand the toll that untreated ADHD takes on children, adults and families — from fractured educational journeys to unemployment, depression, addiction and even suicide. These are not theoretical risks but daily realities for many South Africans. And yet one of the biggest obstacles that locks people out of treatment — our own healthcare policies — remains unchanged.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store